Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
Rehovot, Israel, and Hoboken, NJ, August 7, 2024 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday, August 14, 2024.
以色列Rehovot和新澤西州Hoboken, 2024年8月7日 - Kamada Ltd.（納斯達克股票代碼：KMDA; TASE：KMDA.TA）是一家商業全球生物製藥公司，擁有一系列用於罕見和嚴重病症的上市產品系列，並是特殊血漿衍生領域的領導者，今天宣佈將於2024年8月14日星期三美國股市開盤前發佈截至2024年6月30日的第二季度和上半年的財務業績。
Kamada management will host an investment community conference call on Wednesday, August 14 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263 (International) using conference ID 13747542. The call will also be webcast live on the Internet at:
Kamada管理團隊將於美國東部時間8月14日上午8:30主持投資社區電話會議，討論這些結果並回答問題。 股東和其他有興趣的方參加電話會議，可撥打1-877-407-0792（美國內）或1-809-406-247（以色列國內）或1-201-689-8263（國際撥號），使用會議ID：13747542。 該電話會議也將通過Internet直播：
The call will also be archived for 90 days on the Company's website at .
此電話會議的歸檔也將在公司網站上保留90天。
About Kamada
Kamada Ltd. (the "Company") is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company's strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company's commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB, CYTOGAM, WINRHO SDF, VARIZIG, HEPAGAM B and GLASSIA, as well as KAMRAB, KAMRHO (D) and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company's commercial operation, it invests in research and development of new product candidates. The Company's leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company's controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.
關於kamada
Kamada Ltd.（“公司”）是一家商業全球生物製藥公司，擁有一系列用於罕見和嚴重病症的上市產品系列，並是特殊血漿衍生領域的領導者，專注於治療有限治療選擇的疾病。 公司還正在推進創新的開發管線，以針對顯著未滿足的醫療需求領域。 公司的策略着重於從其重要的商業催化劑以及其血漿衍生物和生物製藥領域的製造和開發專業知識中推動盈利增長。 公司的商業產品組合包括6個FDA批准的血漿衍生生物製藥產品：KEDRAb，CYTOGAm，WINRHO SDF，VARIZIG，HEPAGAm b和GLASSIA，以及KAMRAb，KAMRHO（D）和兩種馬血清製劑產品。 該公司直接分銷其商業產品組合，以及通過戰略合作伙伴或第三方分銷商在包括美國，加拿大，以色列，俄羅斯，阿根廷，巴西，印度，澳大利亞和拉丁美洲，歐洲，中東和亞洲其他國家的30多個國家進行分銷。 該公司利用其在以色列市場的專業知識和存在，分銷來自國際製造商的25多種藥物產品供以色列使用。 近年來，該公司將十一種生物仿製藥產品添加到其以色列分銷組合中，預計將通過2028年在以色列推出，前提是獲得歐洲藥品管理局（EMA）和以色列衛生部的批准。 該公司擁有位於德克薩斯州博蒙特的FDA許可血漿採集中心，目前專門從事用於製造KAMRHO（D），KAMRAb和KEDRAb的高免疫血漿的採集。 除了公司的商業運營外，它還投資於新產品候選的研究和開發。 公司的主要調查產品是用於治療AAt缺陷的吸入式AAt，目前正在進行隨機，雙盲，安慰劑對照的關鍵III期InnovAATe臨床試驗。 以色列領先的私募股權公司FIMI機會基金是該公司的控股股東，其享有約38％的普通股外的利益。
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
聯繫方式：
Chaime Orlev
致富金融(臨時代碼)
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
(212) 915-2578
britchie@LifeSciAdvisors.com
Brian Ritchie
LifeSci Advisors，LLC
（212）915-2578
britchie@LifeSciAdvisors.com
譯文內容由第三人軟體翻譯。